Immune drug discovery from venoms by Jimenez, Rocio et al.
Accepted Manuscript
Immune drug discovery from venoms
Rocio Jimenez, Maria P. Ikonomopoulou, J.A. Lopez, John J. Miles
PII: S0041-0101(17)30352-5
DOI: 10.1016/j.toxicon.2017.11.006
Reference: TOXCON 5763
To appear in: Toxicon
Received Date: 18 July 2017
Revised Date: 14 November 2017
Accepted Date: 18 November 2017
Please cite this article as: Jimenez, R., Ikonomopoulou, M.P., Lopez, J.A., Miles, J.J., Immune drug
discovery from venoms, Toxicon (2017), doi: 10.1016/j.toxicon.2017.11.006.
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to
our customers we are providing this early version of the manuscript. The manuscript will undergo
copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please
note that during the production process errors may be discovered which could affect the content, and all
legal disclaimers that apply to the journal pertain.
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
1 
 
 
Immune drug discovery from venoms  
 
 
 
Rocio Jimenez1,2, Maria P. Ikonomopoulou2,3, J.A. Lopez1,2 and John J. 
Miles1,2,3,4,5 
 
1. Griffith University, School of Natural Sciences, Brisbane, Queensland, Australia 
2. QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia 
3. School of Medicine, The University of Queensland, Brisbane, Australia 
4. Centre for Biodiscovery and Molecular Development of Therapeutics, AITHM, James Cook 
University, Cairns, Queensland, Australia 
5. Institute of Infection and Immunity, Cardiff University School of Medicine, Heath Park, 
Cardiff, United Kingdom 
 
Corresponding author: A/Prof John J. Miles, Molecular Immunology Laboratory, Centre for 
Biodiscovery and Molecular Development of Therapeutics, AITHM, James Cook University, 
Cairns, Queensland, Australia E-mail: john.miles@jcu.edu.au. 
 
Key words: venom, toxin, therapeutic, immune modulation, immune system 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
2 
 
Abstract   
 
This review catalogues recent advances in knowledge on venoms as standalone therapeutic 
agents or as blueprints for drug design, with an emphasis on venom-derived compounds that affects 
the immune system. We discuss venoms and venom-derived compounds that affect total immune 
cell numbers, immune cell proliferation, immune cell migration, immune cell phenotype and 
cytokine secretion. Identifying novel compounds that ‘tune’ the system, up-regulating the immune 
response during infectious disease and cancer and down-regulating the immune response during 
autoimmunity, will greatly expand the tool kit of human immunotherapeutics. Targeting these 
pathways may also open therapeutic options that alleviate symptoms of envenomation. Finally, 
combining recent advances in venomics with progress in low cost, high-throughput screening 
platforms will no doubt yield hundreds of prototype immune modulating compounds in the coming 
years.  
 
Highlights 
• Up to date review of venom and venom-derived compounds involved in immune 
modulation. 
• Catalog of FDA approved venom-derived therapeutics. 
• Mechanisms of immune modulation by snake, scorpion, bee and sea anemone secretions. 
• Avenues for future translation of venom-derived immune modulators.  
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1. Introduction 
There are approximately 8.7 million different species on Earth, (Mora et al., 2011) many of 
which produce venoms that have been refined over 600 million years of evolution for optimal 
potency and selectivity (Mauri et al., 2017). Animal venoms have been used to treat various 
diseases by many cultures for millennia. In mithridatism practice, individuals regularly exposed 
themselves to small amounts of venom until immunity developed (Valle et al., 2012). In Chinese 
traditional medicine, venom from the glands of Bufo bufo gargarizans was used for treating 
infection and inflammation (Meng et al., 2009; Qi et al., 2014).   
Venom is a complex mixture of peptides, proteins, enzymes, salts, and non-protein 
constituents. In terms of numbers of species, there are currently 600 leech species (Sket and 
Trontelj, 2008), 800 tick species (Cabezas-Cruz and Valdes, 2014), 3,000 snake species (Wagstaff 
et al., 2006), 700 cone snail species (Puillandre et al., 2014), 1,100 bat species (Jan et al., 2012), 
2,000 scorpion species (Cao et al., 2014), 10,000 cnidarians species (Cegolon et al., 2013) and 
46,000 spider species (World_Spider_Catalog, 2017), although not all these species are venomous 
or dangerous to humans. Other venomous animal include centipedes, scorpions, octopus, sea 
anemones and fish (Fry et al., 2009). Advances in proteomic, genomic and transcriptomic platforms 
are rapidly defining animal venom complexity (termed venomics) and are helping facilitate the 
translation of venom-derived compounds to novel therapeutics (Haney et al., 2014; Safavi-Hemami 
et al., 2014; Undheim et al., 2013). To date, six venom-derived drugs have been approved by FDA 
(Table 1) and many others are in preclinical development or clinical trials (King, 2011). The 
majority of venoms investigated thus far have been derived from snakes, due to the large amounts 
of venom these species produce for research (King, 2011). However, it should be noted that the 
venom yield is higher in captive snakes compared to the wild snakes and the amount of venom can 
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be different depending on the type of bite, specifically a hunting or defensive bite (Mirtschin et al., 
2006). Venoms and venom-derived compounds are known to activate or inhibit the immune 
response and synthetic venom-derived peptides are capable of modulating the human immune 
system. For example, the ShK peptide from the venom of sea anemone inhibits the Kv1.3 ion 
channel in T effector memory (TEM) cells, producing decreased cell proliferation and suppression of 
IL-2 production (Beeton et al., 2005). Furthermore, a derivative of ShK (dalazatide) recently 
completed a successful Phase I clinical trial in psoriasis patients (Tarcha et al., 2017).  
The systematic study of the venom components and their interaction with the immune 
system may reveal novel therapeutics for a plethora of human diseases and therapeutics against 
envenomation symptoms. Venoms are engaged by the immune system and a response is generated 
to counterbalance their effects. This recognition is chiefly mediated by inflammation combined with 
the release of anti-inflammatory mediators in order to maintain homeostasis (Farsky et al., 2005; 
Leon et al., 2011; Petricevich, 2010). Crude venom and venom-derived compounds from spider, 
snake, scorpion and bee venom trigger inflammation (de Lima and Brochetto-Braga, 2003; Farsky 
et al., 2005; Petricevich, 2010; Rahmani et al., 2014). Inflammation refers to the complex reaction 
to harmful or noxious stimuli, including vascular changes, cell recruitment and cytokine release. 
The clinical signs of inflammation include redness, pain, heat, swelling and loss of function. It is 
also one of the steps in healing (Voronov et al., 1999) . The immune system has evolved for 
approximately 1,000 million years as a defensive system to protect the host (Buchmann, 2014). 
Initially, innate or natural immunity protects the body with a non-specific and fast response 
regulated through two lines of defense. The first line is comprised of physical and chemical barriers 
including skin, mucosa, cilia, tears, sweat, urine and bacterial flora. When the first defense line falls 
the second line is activated that includes the inflammatory response. Here diverse cell types are 
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recruited (i.e. mast cells, neutrophils and eosinophils) and other chemical barriers such as the 
complement cascade are activated. The adaptive response can also be activated to generate 
immunological memory. Adaptive immunity is chiefly composed of T cells and B cells. T cells 
require antigen presentation by antigen presenting cells (APCs) via the Major Histocompatibility 
Complex (MHC). When APCs present antigen to T cells they become activated and secrete 
cytokines. B cells produce antibodies and plasma cells, the mature form of B cells, belong to the 
humoral immunity arm (Cota and Midwinter; Warrington et al., 2011). This review catalogues the 
potential of venom and their components as drugs or drug scaffolds, focusing on their potential as 
novel modulators of these immune cells (Figure 1). 
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2. The immune response to venom 
2.1 Snake venom and immune modulation 
Snake venom is synthetized by glands under the eye and they comprise a cluster of proteins 
that are determined by diet, geography (Daltry et al., 1996), age and gender (Woltering, 2012). 
Snake venom proteins are mixed with other components such as enzymes, amino acids, 
carbohydrates, lipids, amines and metal components (i.e. Zn+, Mg+, K+, Ca+ and Na+). Snake 
envenomation is a significant public health burden in tropics with over five million bites annually 
according to the World Health Organization (WHO) (Ahmed et al., 2008; Chippaux, 1998).  
Post envenomation, venom components generate an immune response (Leon et al., 2011). 
Both the innate and adaptive immune arms then attempt to neutralize the venom components. The 
innate immune response commences first and triggers a non-specific inflammatory cascade 
mediated by neutrophils, eosinophils, basophils and macrophages that phagocyte antigen and 
release cytokines (Nicholson, 2016). Mast cells release histamine to expand the blood vessels 
enhancing cell recrutiment and migration. Leukocytes and mast cells produce prostaglandin D2 
(PGD2) that vasodilates and permeabilizes vessels. Prostaglandins also stimulate nerve endings 
causing pain (Ricciotti and FitzGerald, 2011; Urb and Sheppard, 2012). Bradykinins are released 
that modify cell junctions allowing neutrophils to migrate to the site of injury (Golias et al., 2007; 
Sukriti et al., 2014). Nitric oxide (NO) is a gas produced by endothelial cells that functions as a 
signaling molecule. NO is involved in the relaxation of blood vessels and can perform mediator 
activities in immune cells such as macrophages, neutrophils, APCs and T cells (Coleman, 2001). 
Snake venom is known to induce these mediators after envenomation. For example, the venom of 
Bothrops erythromelas induces NO production in murine splenocytes (Luna et al., 2011) and the 
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venom from Bothrops jararacussu enhances neutrophil chemotaxis (Wanderley et al., 2014). Snake 
envenomation can cause an increase of neutrophils and lymphocyte counts and one study found that 
an elevated neutrophil/lymphocyte ratio correlated with longer periods of hospitalization (Elbey et 
al., 2017), with selective proliferation likely due snake-derivied L-amino acid oxidases (Pontes et 
al., 2016; Wei et al., 2009). Snake venom can induce systemic and local inflammation and it is well 
documented that the genus Bothrops can induce severe inflammation. In a murine model, the snake 
venom from Bothrops asper enhanced the production of IL-6, TNFα and eicosanoids (Zamuner et 
al., 2005) and venom-derived phospholipase A2s (PLA2s) improved phagocytic activity of 
macrophages in vitro (Rueda et al., 2013). 
When the inflammatory response is generated by external dangers the complement system 
activates a sequence of proteins that induces cell lysis and antigen presentation to the adaptive 
immune system. The activation of complement is part of the innate immune response and includes 
more than 30 proteins (Sarma and Ward, 2011). There are three biochemical pathways; the classic 
pathway, the alternative pathway and lectin pathway (Sarma and Ward, 2011). The main role of the 
complement system is to amplify the immune response through the stimulation of phagocytosis and 
cell killing (Sarma and Ward, 2011). Venom from Bothrops jararacussu and Bothrops pirajai can 
activate the classic and lectin pathways (Ayres et al., 2015). Venom from the Elapidae family 
Micrurus genus can also activate a specific complement cascade that induces B cell and T cell 
function (Tanaka et al., 2012). A P-I metalloproteinase derived from the venom of Bothrops pirajai 
can activate complement proteins that induce mast cells to produce histamine, enhancing 
phagocytosis and enhancing immune cell migration (Pidde-Queiroz et al., 2013). Similarly, venom 
from Daboia Russelii can activate complement proteins and induce IL-6 and IL-10 (Stone et al., 
2013). Conversely, a P-III metalloproteinase from Naja naja atra venom is considered an 
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anticomplement molecule (Sun and Bao, 2010). Another study found that Naja naja atra venom 
enhanced innate and humoral immune responses while inhibiting CD4+ and CD8+ T cell 
proliferation in response to mitogen (Kou et al., 2014). Naja naja atra venom also induced 
production of IFNγ and IL-4 and inhibited IL-17 production. Mice injected with Crotalus durissus 
terrificus venom showed increased plasma levels of IL-4, IL-5, IL-6, TNFα, IL-10 and NO 
(Hernandez Cruz et al., 2008) and decreased phagocytosis by neutrophils (Lima et al., 2012). A L-
amino acid oxidase from Agkistrodon blomhoffii ussurensis venom induced IL-2, IL-6 and IL-12 
from primary human monocytes and T cells (Wei et al., 2007)  and a PLA2 from Bothrops leucurus 
venom induced IL-1β, IL-6, IL-12p40 and TNFα from primary human mononuclear cells (Nunes et 
al., 2011). Snake venom can also suppress the immune system with Naja kaouthia venom able to 
protect against induced arthritis in rats (Gomes et al., 2010). 
2.2 Scorpion venom and immune modulation 
Scorpions are arthropods that have evolved for >400 million years (Ma et al., 2012) and 
Buthidae is the family with medical significance (Smith et al., 2011). Scorpion venom is comprised 
of proteins, enzymes, peptides, amino acids, carbohydrates, inorganic salts, lipids and amines 
(Quintero-Hernández et al., 2013) and shares similarities with tick and spider venom (Cordeiro et 
al., 2015). Scorpion venom is also rich in neurotoxins that can cause alterations in the central 
nervous system (Watt and Simard, 1984). Scorpion envenomation is a significant public health 
burden in several tropical and subtropical countries such as Brazil, (Furtado Sda et al., 2016)  
Mexico, (Isbister  and Bawaskar 2014) and Iran (Jalali and Rahim, 2014). In addition, over one 
million cases are reported globally every year (Isbister  and Bawaskar 2014). Clinical symptoms in 
envenomed patients include sweating, hypertension, nausea, extreme pain, vomiting, tachycardia 
and convulsions (Isbister  and Bawaskar 2014) and envenomation can induce a systemic 
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inflammatory response syndrome, a result of abnormal cytokine production (Voronov et al., 1999) . 
Scorpion venom is known to interact with Na+, K+, Ca+ and Cl- ion channels (Quintero-Hernández 
et al., 2013).  
Previous studies have shown that the main cytokines released in response to scorpion 
envenomation are IL-1, IL-6 and TNFα (Fukuhara et al., 2003; Jalali et al., 2011). One study 
showed that systemic IL-6 plays an important role in scorpion envenomation (Sofer et al., 1996). In 
another scorpion envenomation study, there was an increase of systemic IL-6, soluble IL-6 receptor, 
TNFα, and RANTES, with high levels correlating with fatal outcomes (Abdel-Haleem et al., 2006). 
Venom from Androctus australis hector, Centruroides noxius and Tityus serrulatus can initiate 
systemic IL-1 release in humans, triggering a complex cascade of other inflammatory/regulatory 
cytokines including IL-6, IL-10 and TNFα (Petricevich, 2010). Another study showed that Tityus 
serrulatus envenomation initiated systemic release of IL-1, IL-6, IL-8, TNFα and IL-10 (Fukuhara 
et al., 2003).  
Cytokines can be released at different time points depending on the cytokine and the 
stimulus (Sullivan et al., 2000). Experiments performed on rats have shown that the plasma 
cytokines IL-1, IL-6 and TNFα peak three hours post injection of Mesobuthus eupeus venom and 
that antivenom can dampen the inflammatory response (Razi Jalali et al., 2015). The scorpion 
venom of Tityus serrulatus and its fractions were tested in a murine macrophage cell line pretreated 
with the mitogen lipopolysaccharide (LPS). Crude venom and two fractions augmented TNFα, IL-6 
and NO release. In contrast, a separate fraction inhibited the release of TNFα and IL-6 and induced 
IL-10 suggesting anti-inflammatory activity (Zoccal et al., 2011). The venom of Androctonus 
crassicauda is known to enhance IL-12 production in human monocytes (Saadi et al., 2015). IL-12 
is a pleiotropic cytokine driving T helper 1 (Th1) differentiation, IFNγ production, and T cell 
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proliferation (Miles et al., 2015; Saadi et al., 2015). T cells are central for anti-pathogen and anti-
cancer immunity and their dysfunction underlies autoimmunity (Miles et al., 2011). Additionally, 
the venom of the Hemiscorpius lepturus induces IL-12 release from human monocytes in vitro 
(Hadaddezfuli et al., 2015) and a fraction from Tityus serrulatus venom induced IL-1, IL-6, TNFα 
and IL-10 from murine monocytes in vitro (Petricevich et al., 2007). Venoms can also interfere with 
immune cell proliferation. The venom of Tityus serrulatus increases IL-6 secretion in PBMC and 
inhibits proliferation in T cells activated by mitogen (Casella-Martins et al., 2015). 
The recognition of external threat is performed by Toll-like receptors (TLRs) which are 
membrane-spanning proteins in the innate immune system, mainly expressed in macrophages and 
dendritic cells (DCs) (Kawai and Akira, 2010). TLRs are able to recognize ligands from microbes 
(bacteria, viruses and fungi) and then activate immune responses (Kawai and Akira, 2010). Ten 
TLRs have been identified in humans and TLR agonists induce activation and maturation of the 
immune system (Kawai and Akira, 2010).Venoms are known to engage the innate immune system 
including TLRs. For example, crude Tityus serrulatus venom and a venom fraction are sensed by 
murine TLR2 and TLR4 and induce the NF-κB and MAPK signaling pathways in macrophages 
resulting in release of IL-6, TNFα, PGE2 and LTB4 (Zoccal et al., 2014). Tityus serrulatus venom 
fractions have also been observed to modulate APC phenotype and function (Petricevich et al., 
2008).  
The interaction between venom-derived compounds and ion channels and has been well 
studied (King, 2011). Venom-derived peptides are highly selective for these targets, and they have 
been described as promising candidates for new therapeutic approaches and drug development 
(Bagal et al., 2013). Ion channels, specifically K+ channels, are involved in T cell activation and are 
a chief target for immunomodulation. Other lineages also express K+ channels (DCs, monocytes, 
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and macrophages) (Zhao et al., 2015). Scorpion venom and its components can manipulate K+ 
channels for immune modulation (Hmed et al., 2013; Petricevich et al., 2007). For example, several 
scorpion peptides are known to inhibit K+ ion channels (Dutertre and Lewis, 2010; Swartz, 2013) 
including Margatoxin (MgTX) peptide from the venom of Centruroides margaritatus. MgTX can 
inhibit Kv 1.3 channels expressed by T cells and B cells (Bartok et al., 2014; Garcia-Calvo et al., 
1993). A second example is Kaliotoxin (KTx) peptide from the venom of Androctonus 
mauretanicus mauretanicus which can inhibit both Ca+ and K+ channels (Crest et al., 1992). 
2.3 Bee Venom and immune modulation  
The venom of Apis mellifera also has applications for immune modulation. 50-60% of the 
dry venom compises a single melittin peptide (Raghuraman and Chattopadhyay, 2007) and 2-3% of 
the dry venom comprises the apamin peptide (Gmachl and Kreil, 1995). Bee venom also contains 
enzymes such as hyaluronidase, PLA2 and histamine (Hwang et al., 2015).  
DCs are the chief lineage for antigen presentation and they initiate both naïve and memory T 
cell responses (Randolph et al., 2005). Immature DCs are able to digest antigens by endocytosis, 
micropinocytosis and phagocytosis and, once they uptake antigen, DC migrate to lymph nodes 
where they mature and encounter T cells (Randolph et al., 2005). DCs express well known surface 
markers and costimulatory molecules that increase in expression during maturation (CD40, CD80, 
CD83 and CD86) and a mature DC phenotype correlates directly with potent T cell responses 
(Hubo et al., 2013). PLA2 from bee venom can enhance the maturation of DC and PLA2, in 
combination with TNFα and IL-1β, can induce the upregulation of costimulatory molecules CD83, 
CD86, both important for T cell stimulation (Aerts-Toegaert et al., 2007; Jeannin et al., 2000; Van 
Kaer, 2015). Immune cells express classic antigen presenting molecules MHC class I and class II 
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but can also express non-classical molecules including CD1 (Rossjohn et al., 2015). Bee venom 
PLA2 can activate human T cells via CD1 molecules (Bourgeois et al., 2015) and can also induce a 
Th2 response via the release of IL-33 (Palm et al., 2013), a cytokine common in the skin and 
intestine (Miller, 2011). Thus, bee venom is a potent immune modulator and it has been used for a 
over a hundred years in autoimmune diseases such as rheumatoid arthritis and allergic disorders like 
asthma (Pak, 2016). Bee venom is known to induce T regulatory (Treg) cells (Park et al., 2015), an 
important regulatory lineage that corrects erroneous activities of other T cell subsets. Treg cells 
produce TGFβ and IL-10 that suppress the immune system and therefore reduce autoimmunity, 
inflammation and allergy (Wan and Flavell, 2007). Bee venom is known to induce Treg populations 
effectively and therapeutic application decreases inflammation of the bronchi in a murine asthma 
model (Choi et al., 2013).  
2.4 Sea anemone toxin and immune modulation 
A toxin rather than a venom, the ShK peptide from derived from the Stoichactis helianthus 
anemone (Pennington et al., 2012) shows promise as a selective immune suppressor (Norton et al., 
2004). Analogs of the toxin have shown similar activities and modes of action (Lanigan et al., 
2001). The anemone produces the toxin for protection against predators. Autoimmunity is the 
failure of the immune system to differentiate external threats from healthy operations resulting in 
unintended tissue damage. Most autoimmune diseases have no cures and researchers are actively 
exploring natural sources for novel therapeutics (Smallwood et al., 2017). The ShK peptide is 
known to block Kv1.3 channel found on the surface of TEM cells, which are central to the damage 
cascade in autoimmunity (Beeton et al., 2005). The Dalazatide peptide recently underwent clinical 
trials in psoriasis and the patients showed an improvement of this condition. The clinical trial data 
has now been published (Tarcha et al., 2017). 
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3. Conclusions 
Recent advances in omics technologies paired with advances in synthetic peptide production 
and rapid recombinant expression (cell-free systems) is leading to an explosion in basic and applied 
venomics. Indeed, an estimated 20 million venom-derived compounds are thought to remain 
unexplored in nature (Escoubas and King, 2009). Combining advances in venomics with progress in 
low cost, high-throughput screening platforms will no doubt yield hundreds of prototype 
compounds applicable to the ~10,000 diseases known to medicine (WHO). At present, six venom-
derived drugs have been FDA approved with many more in preclinical development and in clinical 
trials. Current research shows that venom has the capacity to induce potent effects on the immune 
response. These include customizer compounds that tune immune cell numbers, phenotype and 
function. For instance, snake and bee venom compounds that regulate immune cell subsets numbers 
and cell trafficking would be useful across autoimmunity, infectious disease and cancer. Snake 
venom compounds that induce IL-2 and IFNγ would be useful in the emerging field of cancer 
immunotherapy and snake venom compounds that augment humoral immunity might be useful as 
adjuvants for antibody-based vaccines. Scorpion venom compounds that induce IL-12 would be 
useful for DC-based vaccines and snake and scorpion venom compounds that induce IL-10 might 
be useful in autoimmune disorders. Snake and scorpion venom compounds that selectively shut off 
T cell and B cell function would also be useful in autoimmune disorders and transplant medicine. 
Additionally, targeting these immune pathways may also open new therapeutic options that help 
alleviate envenomation symptoms associated with immune dysfunction. With these examples in 
mind, it is likely that venom-derived immune drug development is still in its infancy and these data 
emphasize the importance of preserving biodiversity to sustain future discoveries. 
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Table 1. FDA approved therapeutics from venom-derived proteins  
*Bydureon is the long-action mode and derived of Byetta®. The administration of these drugs is in combination with other Diabetes Type 2 
medications. Adapted from (King, 2011). 
 
 
 
 
 
 
 
 
 
 
 
 
Name 
 
Active Ingredients  
 
Indication and Mechanism of Action 
 
Route  
 
 
Year 
 
Derived from 
 Prialt® Ziconotide 
SNX-111 
Non-opioid and 
analgesic 
medication 
Severe and Chronic Pain with 
Neuropathic Origin 
The obstruction of the ion channel by the 
chemical composition of the drug impedes 
the secretion of neurotransmisors, 
blocking the signal of pain to the brain. 
Intrathecal administration 2004 Cone snail 
Conus magus 
Byetta® Exenatide Synthetic Diabetes Type 2 
Increases the release of glucose-dependent 
insulin by the stimulation of pancreatic 
beta-cells. Delays gastric emptying. 
Subcutaneous administration 2005 Gila Monster 
Heloderma suspectum 
*Bydureon® Exenatide Synthetic 
 
Subcutaneous administration 2012 Gila Monster 
Heloderma suspectum 
Angiomax® Bivalirudin Anticoagulant 
Inhibits clot formation, interacts with 
thrombin in cascade coagulation. 
 
Intravenous administration 
 
2000 Medicinal Leech 
Hirudo medicinalis 
Capoten® Captopril Hypertension 
Interfering in the transformation between 
angiotensin I and Angiotensin II by the 
inhibition of angiotensin converting 
enzyme (ACE).  
Oral, tablet 1981 Viper Snake 
Bothrops jararaca 
Aggrastat® 
 
Tirofiban 
Hidrochloride 
Inhibitor of platelet aggregation  
This drug binds to the main platelet 
surface receptor (GP IIb/IIIa).   
Intravenous administration 1999 Viper Snake 
African saw-scaled 
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Reduces the binding of fibrinogen von 
Willebrand factor and ligands to GP 
IIb/IIIa. 
Intravenous administration 1998 Viper Snake 
Sistrurus miliarius 
barbouri 
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Figure 1. Immune pathways modulated by venom 
 
Figure 1. Immune pathways modulated by venom. The innate (blue) and adaptive (red) immune 
arms can be modulated by crude venom and venom components. Cells at the junction of the innate 
and adaptive immune arms, including DCs and APCs (black), can also be modulated by venom and 
venom components. The ability to selectively target each of these subsystems using synthetically-
derived venom components will open novel immunotherapies across infectious disease, cancer and 
autoimmunity.     
